DAIC Articles

Oct 10, 2019 | DAIC Articles
FDA Clears Abbott’s High Sensitivity Troponin-I Blood Test

October 9, 2019 — Abbott recently announced that its Architect Stat High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug Administration (FDA). As one of the most researched troponin diagnostic tests, doctors in the U.S. can now utilize this proven technology to help detect heart attacks faster and more accurately than contemporary troponin […]

Oct 8, 2019 | DAIC Articles
PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study

October 8, 2019 — PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) trial of the company’s Torus stent graft. The novel stent graft platform is designed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). By acquiring early U.S. Food and Drug Administration (FDA) feedback through the pre-submission […]

Oct 8, 2019 | DAIC Articles
360 Degree View of a CTO Atherectomy Revascularization at Henry Ford Hospital

Henry Ford Hospital in Detroit gets a lot of referrals for very sick patients seeking a last resort treatment in its high-risk percutaneous coronary intervention program (CHIP). Many of these are chronic total occlusions (CTOs) of the coronary arteries.  This 360 degree image shows CTO expert Khaldoon Alaswad, M.D., director, cardiac catheterization lab using a Diamondback […]

Oct 2, 2019 | DAIC Articles
IVUS and iFR Video Game App Training Offered by Philips and Level Ex

October 2, 2019 — Philips Healthcare is utilizing Level Ex’s video game app design expertise to train interventional cardiologists on how and when to use intravascular ultrasound (IVUS) and Instant Wave-Free Ratio (iFR). Both technologies are now integrated into select levels within the Cardio Ex cath lab training app.

Oct 2, 2019 | DAIC Articles
New Acurate neo Self-expanding TAVR Device Does Not Meet Non-Inferiority Compared to Sapien 3

October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate neo transcatheter heart valve with the Edwards Lifesciences Sapien 3 transcatheter aortic valve replacement (TAVR) device did not meet non-inferiority in patients with severe aortic stenosis.

Oct 1, 2019 | DAIC Articles
Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT

September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug-coated stent in patients at high risk of bleeding and treated with one-month dual antiplatelet therapy (DAPT) found that both are clinically safe and effective.

Oct 1, 2019 | DAIC Articles
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD

September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) is safe and effective in patients undergoing percutaneous coronary intervention (PCI) for unprotected left main coronary artery (uLMCA) disease. These findings are courtesy of the IDEAL-LM trial, which compared BP-EES plus four months of DAPT to […]

Sep 30, 2019 | DAIC Articles
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients

September 30, 2019 – Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) patients treated with a contemporary drug-eluting stent.

Sep 25, 2019 | DAIC Articles
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival

September 25, 2019 — Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized patients with de novo three-vessel and left main coronary artery disease, according to new research. The late-breaking results from the SYNTAX Extended Survival study were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. […]

Sep 24, 2019 | DAIC Articles
Medtronic Launches Evolut Pro+ TAVR System

September 24, 2019 – Medtronic announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut Pro+ transcatheter aortic valve replacement (TAVR) system. The new-generation Medtronic TAVR system builds off the self-expanding, supra-annular Evolut TAVR platform. The Evolut Pro+ TAVR System includes four valve sizes with an external pericardial tissue wrap that provides advanced […]

X